SUNHO (CHINA) BIOPHARMACEUTICAL CO.,LTD

SunHo is a biopharmaceutical company committed to the discovery, development and commercialization of first-in-class/best-in-class biologics that regulate immune microenvironment by directly modulating both the innate and adaptive immune systems. Leveraging our deep understanding of immunology, we have developed various types of immunotherapies including immunocytokines to treat cancers and autoimmune diseases.

Our commitment to innovation is evident and supported by our proprietary technology platforms, which include (i) AIC™ Platform, a scalable platform mainly concentrated on antibody-cytokine fusion protein development, (ii) ADCC Enhanced Antibody Platform (“AEA™ Platform”), a FUT8 gene knock-out cell line constructed to enhance the cytotoxicity of antibodies, and (iii) Armed Innate Effector Multi-specific Platform (“AIM™ Platform”), a platform that focuses on the development of innate immunity stimulator-based bispecific/multi-specific antibodies. Through our proprietary ...